Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM)
Ciara L Freeman(Moffitt Cancer Center), Krina K. Patel(The University of Texas MD Anderson Cancer Center), Sarah M. Larson(North Carolina State University), Hongxiang Hu(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Sandy W. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Paola Neri(University of Calgary), Julia Piasecki(Université Paris Cité), Susan Bal(University of Alabama at Birmingham), Omar Nadeem(Harvard University), Anupama Kumar, Sarah Johnston(Bristol-Myers Squibb (United States)), Svenja Groeneveld(Bristol-Myers Squibb (United States)), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Nikhil C. Munshi(Harvard University), Nisha Joseph(Emory University), Shinsuke Iida(Nagoya City University), Jaclyn Davis(Bristol-Myers Squibb (United States)), Tara Gregory(Sarah Cannon), Timothy Pulham(Bristol-Myers Squibb (Sweden))
Cited by 0
Related Papers
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505
Molecular Mechanisms of Tumor Angiogenesis
|Genes & Cancer|2011|217
Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy
|Journal of Cell Science|2015|179